The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma
•We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy to investigate the number of cycles associated with the maximum radiological response and progression disease rate.•The maximum radiological response was observed at Cycl...
Gespeichert in:
| Veröffentlicht in: | Urologic oncology 2021-12, Vol.39 (12), p.832.e17-832.e23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 832.e23 |
|---|---|
| container_issue | 12 |
| container_start_page | 832.e17 |
| container_title | Urologic oncology |
| container_volume | 39 |
| creator | Okita, Kazutaka Hatakeyama, Shingo Hagiwara, Kazuhisa Suzuki, Yuichiro Tanaka, Toshikazu Noro, Daisuke Tokui, Noriko Fujita, Naoki Konishi, Sakae Okamoto, Teppei Yoneyama, Tohru Yamamoto, Hayato Yoneyama, Takahiro Hashimoto, Yasuhiro Ohyama, Chikara |
| description | •We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy to investigate the number of cycles associated with the maximum radiological response and progression disease rate.•The maximum radiological response was observed at Cycles 2.•The radiological response was significantly different between Cycle 2 and 4.•We observed 63% of patients with disease progression within the first 4 cycles•Our results suggested that less than half of patients were a potential candidate for maintenance immunotherapy after the first 4 cycles.
The number of cycles of platinum-based first-line chemotherapy associated with the maximum tumor response in patients with advanced urothelial carcinoma is not yet established. We investigated the association between the number of cycles and the maximum radiological response of first-line chemotherapy.
We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and December 2020. The primary outcome was estimating the number of cycles associated with the maximum radiological response and progression disease rate within the 6 cycles. The radiological response was evaluated by the RECIST v1.1. The secondary outcomes included the difference in radiological response rate and the impact on overall survival between the cisplatin-based and carboplatin-based regimens.
The maximum radiological response was -22% at Cycles 2. It was significantly decreased at Cycles 4 (-15%) compared with Cycles 2 (P < 0.001). The progression disease rate within the first 2, 4, and 6 cycles were 21% and 63%, and 84%, respectively. Radiological response was no significant difference between the cisplatin-based and carboplatin-based regimens. However, it was significantly decreased in the carboplatin-based regimen at Cycles 4 (-17%) compared with Cycles 2 (-22%; P = 0.004). Background-adjusted overall survival was not significantly different in between the cisplatin-based and carboplatin-based regimens (hazard rate 1.27; P = 0.337).
The maximum radiological response was -22% at Cycles 2. The radiological response was significantly different between Cycle 2 and 4. More than half of patients had disease progression within the first 4 cycles.
[Display omitted] |
| doi_str_mv | 10.1016/j.urolonc.2021.03.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2515063535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143921001216</els_id><sourcerecordid>2515063535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-6369017f8a8a45f7f98bd46f86afd4dfe1685b81e32c1bc0ad413f515547ddc43</originalsourceid><addsrcrecordid>eNqFkcGOFCEQhonRuLujj6Dh6KVbaGiaPhmzWXWTTbysZ0JD4TBpoIXu1Xkdn1QmM3o1dagK-esvqj6E3lDSUkLF-0O75TSnaNqOdLQlrCWUPkPXVA6s6fgonteaDLKhnI1X6KaUAyGUS0pfoivGpOiFHK_R78c9YHAOzIqTw3ELE-RTtWbQa4C4YnM0M5TT2zLr1VdJM-kCFjufy9rMPgI2ewhp3UPWyxGniIP-5cMWcNbW119-90bPOENZUiyAfcRLdarmBf_06x5r-6SjqZZ1p-oy-6o2OhsfU9Cv0Aun5wKvL3mHvn26e7z90jx8_Xx_-_GhMZx2ayOYGAkdnNRS894NbpST5cJJoZ3l1gEVsp8kBdYZOhmiLafM9bTv-WCt4WyH3p19l5x-bFBWFXwxMM86QtqK6qqWCNbX2KH-LDU5lZLBqSX7oPNRUaJOeNRBXfCoEx5FmKp4at_by4htCmD_df3lUQUfzgKoiz55yKqYeqd6Gp8rImWT_8-IP9NxqKU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515063535</pqid></control><display><type>article</type><title>The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Okita, Kazutaka ; Hatakeyama, Shingo ; Hagiwara, Kazuhisa ; Suzuki, Yuichiro ; Tanaka, Toshikazu ; Noro, Daisuke ; Tokui, Noriko ; Fujita, Naoki ; Konishi, Sakae ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</creator><creatorcontrib>Okita, Kazutaka ; Hatakeyama, Shingo ; Hagiwara, Kazuhisa ; Suzuki, Yuichiro ; Tanaka, Toshikazu ; Noro, Daisuke ; Tokui, Noriko ; Fujita, Naoki ; Konishi, Sakae ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</creatorcontrib><description>•We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy to investigate the number of cycles associated with the maximum radiological response and progression disease rate.•The maximum radiological response was observed at Cycles 2.•The radiological response was significantly different between Cycle 2 and 4.•We observed 63% of patients with disease progression within the first 4 cycles•Our results suggested that less than half of patients were a potential candidate for maintenance immunotherapy after the first 4 cycles.
The number of cycles of platinum-based first-line chemotherapy associated with the maximum tumor response in patients with advanced urothelial carcinoma is not yet established. We investigated the association between the number of cycles and the maximum radiological response of first-line chemotherapy.
We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and December 2020. The primary outcome was estimating the number of cycles associated with the maximum radiological response and progression disease rate within the 6 cycles. The radiological response was evaluated by the RECIST v1.1. The secondary outcomes included the difference in radiological response rate and the impact on overall survival between the cisplatin-based and carboplatin-based regimens.
The maximum radiological response was -22% at Cycles 2. It was significantly decreased at Cycles 4 (-15%) compared with Cycles 2 (P < 0.001). The progression disease rate within the first 2, 4, and 6 cycles were 21% and 63%, and 84%, respectively. Radiological response was no significant difference between the cisplatin-based and carboplatin-based regimens. However, it was significantly decreased in the carboplatin-based regimen at Cycles 4 (-17%) compared with Cycles 2 (-22%; P = 0.004). Background-adjusted overall survival was not significantly different in between the cisplatin-based and carboplatin-based regimens (hazard rate 1.27; P = 0.337).
The maximum radiological response was -22% at Cycles 2. The radiological response was significantly different between Cycle 2 and 4. More than half of patients had disease progression within the first 4 cycles.
[Display omitted]</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2021.03.011</identifier><identifier>PMID: 33865689</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin ; cisplatin ; Female ; Humans ; Male ; Middle Aged ; Platinum - pharmacology ; Platinum - therapeutic use ; Prognosis ; Radiological response ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - radiotherapy ; Urothelial carcinoma</subject><ispartof>Urologic oncology, 2021-12, Vol.39 (12), p.832.e17-832.e23</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-6369017f8a8a45f7f98bd46f86afd4dfe1685b81e32c1bc0ad413f515547ddc43</citedby><cites>FETCH-LOGICAL-c412t-6369017f8a8a45f7f98bd46f86afd4dfe1685b81e32c1bc0ad413f515547ddc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1078143921001216$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33865689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okita, Kazutaka</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Hagiwara, Kazuhisa</creatorcontrib><creatorcontrib>Suzuki, Yuichiro</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Noro, Daisuke</creatorcontrib><creatorcontrib>Tokui, Noriko</creatorcontrib><creatorcontrib>Fujita, Naoki</creatorcontrib><creatorcontrib>Konishi, Sakae</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yoneyama, Tohru</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><title>The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy to investigate the number of cycles associated with the maximum radiological response and progression disease rate.•The maximum radiological response was observed at Cycles 2.•The radiological response was significantly different between Cycle 2 and 4.•We observed 63% of patients with disease progression within the first 4 cycles•Our results suggested that less than half of patients were a potential candidate for maintenance immunotherapy after the first 4 cycles.
The number of cycles of platinum-based first-line chemotherapy associated with the maximum tumor response in patients with advanced urothelial carcinoma is not yet established. We investigated the association between the number of cycles and the maximum radiological response of first-line chemotherapy.
We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and December 2020. The primary outcome was estimating the number of cycles associated with the maximum radiological response and progression disease rate within the 6 cycles. The radiological response was evaluated by the RECIST v1.1. The secondary outcomes included the difference in radiological response rate and the impact on overall survival between the cisplatin-based and carboplatin-based regimens.
The maximum radiological response was -22% at Cycles 2. It was significantly decreased at Cycles 4 (-15%) compared with Cycles 2 (P < 0.001). The progression disease rate within the first 2, 4, and 6 cycles were 21% and 63%, and 84%, respectively. Radiological response was no significant difference between the cisplatin-based and carboplatin-based regimens. However, it was significantly decreased in the carboplatin-based regimen at Cycles 4 (-17%) compared with Cycles 2 (-22%; P = 0.004). Background-adjusted overall survival was not significantly different in between the cisplatin-based and carboplatin-based regimens (hazard rate 1.27; P = 0.337).
The maximum radiological response was -22% at Cycles 2. The radiological response was significantly different between Cycle 2 and 4. More than half of patients had disease progression within the first 4 cycles.
[Display omitted]</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin</subject><subject>cisplatin</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platinum - pharmacology</subject><subject>Platinum - therapeutic use</subject><subject>Prognosis</subject><subject>Radiological response</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - radiotherapy</subject><subject>Urothelial carcinoma</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcGOFCEQhonRuLujj6Dh6KVbaGiaPhmzWXWTTbysZ0JD4TBpoIXu1Xkdn1QmM3o1dagK-esvqj6E3lDSUkLF-0O75TSnaNqOdLQlrCWUPkPXVA6s6fgonteaDLKhnI1X6KaUAyGUS0pfoivGpOiFHK_R78c9YHAOzIqTw3ELE-RTtWbQa4C4YnM0M5TT2zLr1VdJM-kCFjufy9rMPgI2ewhp3UPWyxGniIP-5cMWcNbW119-90bPOENZUiyAfcRLdarmBf_06x5r-6SjqZZ1p-oy-6o2OhsfU9Cv0Aun5wKvL3mHvn26e7z90jx8_Xx_-_GhMZx2ayOYGAkdnNRS894NbpST5cJJoZ3l1gEVsp8kBdYZOhmiLafM9bTv-WCt4WyH3p19l5x-bFBWFXwxMM86QtqK6qqWCNbX2KH-LDU5lZLBqSX7oPNRUaJOeNRBXfCoEx5FmKp4at_by4htCmD_df3lUQUfzgKoiz55yKqYeqd6Gp8rImWT_8-IP9NxqKU</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Okita, Kazutaka</creator><creator>Hatakeyama, Shingo</creator><creator>Hagiwara, Kazuhisa</creator><creator>Suzuki, Yuichiro</creator><creator>Tanaka, Toshikazu</creator><creator>Noro, Daisuke</creator><creator>Tokui, Noriko</creator><creator>Fujita, Naoki</creator><creator>Konishi, Sakae</creator><creator>Okamoto, Teppei</creator><creator>Yoneyama, Tohru</creator><creator>Yamamoto, Hayato</creator><creator>Yoneyama, Takahiro</creator><creator>Hashimoto, Yasuhiro</creator><creator>Ohyama, Chikara</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma</title><author>Okita, Kazutaka ; Hatakeyama, Shingo ; Hagiwara, Kazuhisa ; Suzuki, Yuichiro ; Tanaka, Toshikazu ; Noro, Daisuke ; Tokui, Noriko ; Fujita, Naoki ; Konishi, Sakae ; Okamoto, Teppei ; Yoneyama, Tohru ; Yamamoto, Hayato ; Yoneyama, Takahiro ; Hashimoto, Yasuhiro ; Ohyama, Chikara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-6369017f8a8a45f7f98bd46f86afd4dfe1685b81e32c1bc0ad413f515547ddc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin</topic><topic>cisplatin</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platinum - pharmacology</topic><topic>Platinum - therapeutic use</topic><topic>Prognosis</topic><topic>Radiological response</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - radiotherapy</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okita, Kazutaka</creatorcontrib><creatorcontrib>Hatakeyama, Shingo</creatorcontrib><creatorcontrib>Hagiwara, Kazuhisa</creatorcontrib><creatorcontrib>Suzuki, Yuichiro</creatorcontrib><creatorcontrib>Tanaka, Toshikazu</creatorcontrib><creatorcontrib>Noro, Daisuke</creatorcontrib><creatorcontrib>Tokui, Noriko</creatorcontrib><creatorcontrib>Fujita, Naoki</creatorcontrib><creatorcontrib>Konishi, Sakae</creatorcontrib><creatorcontrib>Okamoto, Teppei</creatorcontrib><creatorcontrib>Yoneyama, Tohru</creatorcontrib><creatorcontrib>Yamamoto, Hayato</creatorcontrib><creatorcontrib>Yoneyama, Takahiro</creatorcontrib><creatorcontrib>Hashimoto, Yasuhiro</creatorcontrib><creatorcontrib>Ohyama, Chikara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okita, Kazutaka</au><au>Hatakeyama, Shingo</au><au>Hagiwara, Kazuhisa</au><au>Suzuki, Yuichiro</au><au>Tanaka, Toshikazu</au><au>Noro, Daisuke</au><au>Tokui, Noriko</au><au>Fujita, Naoki</au><au>Konishi, Sakae</au><au>Okamoto, Teppei</au><au>Yoneyama, Tohru</au><au>Yamamoto, Hayato</au><au>Yoneyama, Takahiro</au><au>Hashimoto, Yasuhiro</au><au>Ohyama, Chikara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>39</volume><issue>12</issue><spage>832.e17</spage><epage>832.e23</epage><pages>832.e17-832.e23</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy to investigate the number of cycles associated with the maximum radiological response and progression disease rate.•The maximum radiological response was observed at Cycles 2.•The radiological response was significantly different between Cycle 2 and 4.•We observed 63% of patients with disease progression within the first 4 cycles•Our results suggested that less than half of patients were a potential candidate for maintenance immunotherapy after the first 4 cycles.
The number of cycles of platinum-based first-line chemotherapy associated with the maximum tumor response in patients with advanced urothelial carcinoma is not yet established. We investigated the association between the number of cycles and the maximum radiological response of first-line chemotherapy.
We retrospectively evaluated 167 patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and December 2020. The primary outcome was estimating the number of cycles associated with the maximum radiological response and progression disease rate within the 6 cycles. The radiological response was evaluated by the RECIST v1.1. The secondary outcomes included the difference in radiological response rate and the impact on overall survival between the cisplatin-based and carboplatin-based regimens.
The maximum radiological response was -22% at Cycles 2. It was significantly decreased at Cycles 4 (-15%) compared with Cycles 2 (P < 0.001). The progression disease rate within the first 2, 4, and 6 cycles were 21% and 63%, and 84%, respectively. Radiological response was no significant difference between the cisplatin-based and carboplatin-based regimens. However, it was significantly decreased in the carboplatin-based regimen at Cycles 4 (-17%) compared with Cycles 2 (-22%; P = 0.004). Background-adjusted overall survival was not significantly different in between the cisplatin-based and carboplatin-based regimens (hazard rate 1.27; P = 0.337).
The maximum radiological response was -22% at Cycles 2. The radiological response was significantly different between Cycle 2 and 4. More than half of patients had disease progression within the first 4 cycles.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33865689</pmid><doi>10.1016/j.urolonc.2021.03.011</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1439 |
| ispartof | Urologic oncology, 2021-12, Vol.39 (12), p.832.e17-832.e23 |
| issn | 1078-1439 1873-2496 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2515063535 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin cisplatin Female Humans Male Middle Aged Platinum - pharmacology Platinum - therapeutic use Prognosis Radiological response Retrospective Studies Treatment Outcome Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - radiotherapy Urothelial carcinoma |
| title | The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20number%20of%20treatment%20cycles%20of%20platinum-based%20first-line%20chemotherapy%20on%20maximum%20radiological%20response%20in%20patients%20with%20advanced%20urothelial%20carcinoma&rft.jtitle=Urologic%20oncology&rft.au=Okita,%20Kazutaka&rft.date=2021-12&rft.volume=39&rft.issue=12&rft.spage=832.e17&rft.epage=832.e23&rft.pages=832.e17-832.e23&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2021.03.011&rft_dat=%3Cproquest_cross%3E2515063535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515063535&rft_id=info:pmid/33865689&rft_els_id=S1078143921001216&rfr_iscdi=true |